S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
S&P 500   3,329.62 (+0.39%)
DOW   29,348.10 (+0.17%)
QQQ   223.38 (+0.49%)
Log in
(Ad)
What if you could buy one tiny stock today for $10 - at the center of a growing tech industry - that experts believe will explode a massive 77,400%?

Wall Street legend Paul Mampilly recently identified this as the stock of the century.

Buying up a handful of shares of this small company now could change your life and even make you millions.

NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, Forecast & News

$3.25
+0.10 (+3.17 %)
(As of 01/20/2020 04:00 PM ET)
Today's Range
$3.05
Now: $3.25
$3.25
50-Day Range
$3.11
MA: $3.59
$4.45
52-Week Range
$3.05
Now: $3.25
$7.50
Volume25,716 shs
Average Volume29,762 shs
Market Capitalization$43.42 million
P/E RatioN/A
Dividend YieldN/A
Beta2.17
Merrimack Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that targets biomarker-defined cancers. The company is developing MM-310, an antibody-directed nanotherapeutic, which is in Phase I clinical trial to treat patients with solid tumors. Its preclinical product candidates include MM-401, an agonistic antibody targeting a novel immuno-oncology target; and MM-201, a stabilized agonist-Fc fusion protein targeting death receptors 4 and 5. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MACK
CUSIP59032810
Phone617-441-1000

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.41 per share

Profitability

Net Income$-40,510,000.00

Miscellaneous

Employees27
Market Cap$43.42 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive MACK News and Ratings via Email

Sign-up to receive the latest news and ratings for MACK and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Learn how to make more money in 24 hours than most folks make all year long...This could be the easiest way to turn $5,000 into $196,868.

Merrimack Pharmaceuticals (NASDAQ:MACK) Frequently Asked Questions

What is Merrimack Pharmaceuticals' stock symbol?

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

How often does Merrimack Pharmaceuticals pay dividends? What is the dividend yield for Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals declared a -- dividend on Wednesday, December 4th. Stockholders of record on Monday, December 16th will be paid a dividend of $0.50 per share on Monday, December 23rd. The ex-dividend date is Friday, December 13th. View Merrimack Pharmaceuticals' Dividend History.

When did Merrimack Pharmaceuticals' stock split? How did Merrimack Pharmaceuticals' stock split work?

Shares of Merrimack Pharmaceuticals reverse split before market open on Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) issued its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.05) EPS for the quarter. View Merrimack Pharmaceuticals' Earnings History.

When is Merrimack Pharmaceuticals' next earnings date?

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Merrimack Pharmaceuticals.

Has Merrimack Pharmaceuticals been receiving favorable news coverage?

Media headlines about MACK stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merrimack Pharmaceuticals earned a news impact score of 1.7 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Merrimack Pharmaceuticals.

Are investors shorting Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals saw a decrease in short interest in the month of December. As of December 31st, there was short interest totalling 533,500 shares, a decrease of 6.8% from the December 15th total of 572,700 shares. Based on an average trading volume of 40,500 shares, the short-interest ratio is presently 13.2 days. Approximately 4.2% of the shares of the stock are short sold. View Merrimack Pharmaceuticals' Current Options Chain.

Who are some of Merrimack Pharmaceuticals' key competitors?

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Rite Aid (RAD), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL), Novavax (NVAX), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL) and Verastem (VSTM).

Who are Merrimack Pharmaceuticals' key executives?

Merrimack Pharmaceuticals' management team includes the folowing people:
  • Dr. Richard Peters, Pres, CEO & Director (Age 56)
  • Ms. Jean M. Franchi, CFO & Treasurer (Age 53)
  • Mr. Jeffrey A. Munsie, Gen. Counsel, Head of Corp. Operations & Sec. (Age 42)
  • Dr. Daryl C. Drummond Ph.D., Head of Research (Age 50)
  • Dr. Sergio L. Santillana, Chief Medical Officer (Age 56)

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Merrimack Pharmaceuticals' stock price today?

One share of MACK stock can currently be purchased for approximately $3.25.

How big of a company is Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals has a market capitalization of $43.42 million. Merrimack Pharmaceuticals employs 27 workers across the globe.View Additional Information About Merrimack Pharmaceuticals.

What is Merrimack Pharmaceuticals' official website?

The official website for Merrimack Pharmaceuticals is http://www.merrimackpharma.com/.

How can I contact Merrimack Pharmaceuticals?

Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]


MarketBeat Community Rating for Merrimack Pharmaceuticals (NASDAQ MACK)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  389 (Vote Outperform)
Underperform Votes:  291 (Vote Underperform)
Total Votes:  680
MarketBeat's community ratings are surveys of what our community members think about Merrimack Pharmaceuticals and other stocks. Vote "Outperform" if you believe MACK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MACK will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel